Advances in Breast Cancer: Updates from ESMO 2025
ESMO 2025 highlighted the urgency and breadth of breast cancer research, one of the most diagnosed malignancies worldwide, with major subtypes (HR+, HER2+, and TNBC) responding differently to treatment and developing resistance through distinct mechanisms.
Despite improvements in systemic therapy, long-term survival rates remain suboptimal, and treatment-related toxicities persist. Sequencing also remains uncertain.
This year's ESMO 2025 conference focused on addressing these gaps through targeted combinations, improved tolerability, and biomarker-driven strategies. Notably, the adjuvant use of CDK4/6 inhibitors is redefining the management of high-risk HR+ early-stage disease.
Author's summary: ESMO 2025 updates breast cancer research.
More News
- Bitches in Stitches: Northern Quarter's new all-female comedy shows - Mancunian Matters
- “No Faux King Way”: ‘No Kings’ Protesters Fighting Against Trumpism And White Christian Nationalists - Black Star News
- ‘Tyrant’ teaser hints at Charlize Theron’s boldest role yet in Amazon’s intense thriller
- Samsung taps Nvidia GPUs for AI factory
- Best gaming monitor deal: Save $500 on Samsung 57-inch Odyssey Neo G9
- On first International Day of the Deep Seabed, we seek stewardship and consensus (commentary)
- 'Thief VR: Legacy of Shadow' Comes to All Major VR Headsets in December, New Gameplay Here
- MEG Delays Vote on $5.4B Oil Takeover Yet Again
- IND W Vs AUS W, ICC Women's World Cup 2025: Alyssa Healy Felt Australia Were Not Sharp Enough
- Hurdle hints and answers for October 31, 2025